Nazanin Razazian

Learn More
OBJECTIVE To evaluate the frequency of fatigue and its association with demographic variables and disease specific variables in multiple sclerosis (MS) patients. METHODS In this study, 300 patients (72% female, 28% male) with clinically definite MS admitted to the outpatient MS clinic of Imam Reza Hospital, affiliated to Kermanshah University of Medical(More)
AIM The aim of this randomized, double-blind, parallel-group study was to compare the efficacy and safety of low-dose cinnarizine and sodium valproate in migraine prophylaxis. METHODS A total of 104 patients were treated during a 12-week treatment period. Cinnarizine dose of 25 mg and 200-mg sodium valproate were administered every 12 hours. During(More)
BACKGROUND Amyotrophic lateral sclerosis (ALS) is an incurable progressive neurodegenerative disease and thus the assessment of quality of life (QOL) changes and factors that may influence its course is valuable in the meantime. OBJECTIVES The present study aimed to assess the deterioration rate of QOL and influencing factors in different subgroups of(More)
OBJECTIVES Evidence is mounting that magnet therapy could alleviate the symptoms of multiple sclerosis (MS). This study was performed to test the effects of the pulsing magnetic fields on the paresthesia in MS patients. PATIENTS AND METHODS This study has been conducted as a randomized, double-blind, parallel-group clinical trial during the April 2012 to(More)
OBJECTIVE To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHODS This is a randomized double blind clinical trial conducted between December 2013 and(More)
OBJECTIVE To evaluate the efficacy and safety of carbamazepine, pregabalin, and venlafaxine in patients with painful diabetic neuropathy (PDN). METHODS Our study was performed as a randomized, double-blind, parallel-group clinical trial between December 2012 and December 2013 at Kermanshah University of Medical Sciences, Kermanshah, Iran. Two hundred and(More)
  • 1